Intranasal insulin is a novel treatment for TII diabetes, which has demonstrated promising results in AD, as it improves brain insulin signaling and, consequently, ameliorates the cognitive performance and metabolic integrity of the brain in patients with AD [104]. This evidence concerns the gene INS and diabetes mellitus.